Rethinking Uncomplicated UTI Treatment: Discussion of Aminoglycosides as an Alternative to Carbapenems

February 10, 2025

Debra Fromer, MD

Opinion

Video

An expert briefly describes the study ‘Single Dose Aminoglycosides versus Carbapenems for the Treatment of Uncomplicated Urinary Tract Infections Caused by Extended-Spectrum β-lactamase-phenotype Gram-negative Enterobacterales,” including its objective, design, methodology, results, and key takeaways, and discusses how this data impacts the treatment of inpatient uncomplicated UTIs caused by extended-spectrum β-lactamase-producing Enterobacterales

EP: 1.Unmet Needs in the Management of UTIs

EP: 2.Gepotidacin vs Nitrofurantoin in uUTI: Study Overview and Clinical Implications

Now Viewing

EP: 3.Rethinking Uncomplicated UTI Treatment: Discussion of Aminoglycosides as an Alternative to Carbapenems

EP: 4.Comparing Treatment Options for Acute Pyelonephritis From a Meta-Analysis

EP: 5.Addressing Unmet Needs and Future Outlooks in Treatment of Uncomplicated UTI

Video content above is prompted by the following:

Briefly describe the study “Single Dose Aminoglycosides versus Carbapenems for the Treatment of Uncomplicated Urinary Tract Infections Caused by Extended-spectrum β-lactamase-phenotype Gram-negative Enterobacterales.”
What was the objective of this study?
How was this study designed, and what methodology was used?
What results were presented?
Provide your key takeaways from this study. How does this data impact how you treat inpatient UTIs caused by extended-spectrum β-lactamase-producing Enterobacterales?